mTOR inhibitors and autosomal dominant polycystic kidney disease

N Engl J Med. 2011 Jan 20;364(3):287; author reply 287-9. doi: 10.1056/NEJMc1010845.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Disease Progression
  • Everolimus
  • Glomerular Filtration Rate*
  • Humans
  • Kidney / drug effects
  • Kidney / pathology*
  • Organ Size / drug effects
  • Polycystic Kidney, Autosomal Dominant / drug therapy*
  • Polycystic Kidney, Autosomal Dominant / pathology
  • Polycystic Kidney, Autosomal Dominant / physiopathology
  • Sirolimus / analogs & derivatives*
  • Sirolimus / therapeutic use
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*

Substances

  • Everolimus
  • TOR Serine-Threonine Kinases
  • Sirolimus